VIL1 and hereditary mixed polyposis syndrome: What is clear from this work is that the remarkable phenotypic reversion and long-term survival of Vil1-Grem1 mice commenced early on UCB Ab7326 antibody therapy, providing hope that Grem1 inhibition could offer a preventative therapeutic strategy for HMPS patients.